We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Primerica (PRI) Rallies 17% YTD: Can the Bull Run Continue?
Read MoreHide Full Article
That Primerica, Inc. (PRI - Free Report) stock is favored by investors is further corroborated by its share price movement. Shares of the company have rallied 17.5% year to date against its industry's decrease of 12.4%. However, the stock’s growth lagged the Zacks S&P 500 Composite’s gain of 19.9%. With a market capitalization of $5.1 billion, average volume of shares traded in the past three months was 0.2 million.
Price Performance
What’s Behind the Upside?
The company delivered a positive earnings surprise of 7.2% in second-quarter 2018. Moreover, the bottom line improved nearly 38% during the first half of 2018.
The company continues to benefit from maximizing sales force growth and productivity, expanding protection product offerings, increasing client investment options and developing digital capabilities.
Direct premiums grew 4.6% in the first half of 2018, driven by higher number of new policies issued in recent periods. The company expects adjusted direct premiums to grow around 13.5% in the second half of the year and between 14% and 14.5% in 2018 at Term Life Insurance. Total Revenues improved 13% year over year, driven by incremental premiums on term life insurance policies.
While new recruits increased 2.3%, new life-licensed sales representatives rose nearly 6%. The company estimates life licensed sales forces to consistently grow going forward.
Revenues in Term Life Insurance increased 15% in the first half of 2018. The metric also improved 14% in Investment and Savings Products.
Additionally, the company remains focused on investing in digital development to improve the effectiveness of its representatives and extend client relationships. It intends to spend about $8 million toward this initiative during the second half of 2018.
Return on equity (ROE), a measure of profitability, has been improving over the past many quarters. ROE of 21.1% in the second quarter expanded 260 bps and betters the industry average of 13.2%. This reflects the company’s efficiency in utilizing its shareholders’ funds. The company estimates annualized return on adjusted equity to improve 22% in 2018.
Cash from operations surged 36.8% on increase in cash receipts from collective premium revenues in excess of benefits and claims paid in Term Life Insurance segment.
Banking on its operational efficiency and diverse cash flows, this Zacks Rank #1 (Strong Buy) life insurer has returned $134 million through the first half of 2018. The company intends to repurchase about $200 million shares in 2018.
The Zacks Consensus Estimate for 2018 bottom line reflects 30.1% year-over-year increase on 12.6% higher top line.
Athene Holding, a retirement services company, issues, reinsures and acquires retirement savings products in the United States, the District of Columbia and Germany. The company delivered a 16.54% positive surprise in the earlier reported quarter and sports a Zacks Rank of 1.
FGL Holdings sells individual life insurance products and annuities in the United States. Last reported quarter, it pulled off a 3.85% earnings surprise. The stock is a Zacks #1 Ranked player.
Torchmark provides various life and health insurance products and annuities in the United States, Canada and New Zealand. It came up with a 1.34% beat in the previously reported quarter. It carries a Zacks Rank #2 (Buy).
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions. New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Primerica (PRI) Rallies 17% YTD: Can the Bull Run Continue?
That Primerica, Inc. (PRI - Free Report) stock is favored by investors is further corroborated by its share price movement. Shares of the company have rallied 17.5% year to date against its industry's decrease of 12.4%. However, the stock’s growth lagged the Zacks S&P 500 Composite’s gain of 19.9%. With a market capitalization of $5.1 billion, average volume of shares traded in the past three months was 0.2 million.
Price Performance
What’s Behind the Upside?
The company delivered a positive earnings surprise of 7.2% in second-quarter 2018. Moreover, the bottom line improved nearly 38% during the first half of 2018.
The company continues to benefit from maximizing sales force growth and productivity, expanding protection product offerings, increasing client investment options and developing digital capabilities.
Direct premiums grew 4.6% in the first half of 2018, driven by higher number of new policies issued in recent periods. The company expects adjusted direct premiums to grow around 13.5% in the second half of the year and between 14% and 14.5% in 2018 at Term Life Insurance. Total Revenues improved 13% year over year, driven by incremental premiums on term life insurance policies.
While new recruits increased 2.3%, new life-licensed sales representatives rose nearly 6%. The company estimates life licensed sales forces to consistently grow going forward.
Revenues in Term Life Insurance increased 15% in the first half of 2018. The metric also improved 14% in Investment and Savings Products.
Additionally, the company remains focused on investing in digital development to improve the effectiveness of its representatives and extend client relationships. It intends to spend about $8 million toward this initiative during the second half of 2018.
Return on equity (ROE), a measure of profitability, has been improving over the past many quarters. ROE of 21.1% in the second quarter expanded 260 bps and betters the industry average of 13.2%. This reflects the company’s efficiency in utilizing its shareholders’ funds. The company estimates annualized return on adjusted equity to improve 22% in 2018.
Cash from operations surged 36.8% on increase in cash receipts from collective premium revenues in excess of benefits and claims paid in Term Life Insurance segment.
Banking on its operational efficiency and diverse cash flows, this Zacks Rank #1 (Strong Buy) life insurer has returned $134 million through the first half of 2018. The company intends to repurchase about $200 million shares in 2018.
The Zacks Consensus Estimate for 2018 bottom line reflects 30.1% year-over-year increase on 12.6% higher top line.
Other Stocks to Consider
Investors interested in life insurance industry can also check out some other top-ranked stocks like Athene Holding Ltd. , FGL Holdings (FG - Free Report) and Torchmark Corporation . You can see the complete list of today’s Zacks #1 Rank stocks here.
Athene Holding, a retirement services company, issues, reinsures and acquires retirement savings products in the United States, the District of Columbia and Germany. The company delivered a 16.54% positive surprise in the earlier reported quarter and sports a Zacks Rank of 1.
FGL Holdings sells individual life insurance products and annuities in the United States. Last reported quarter, it pulled off a 3.85% earnings surprise. The stock is a Zacks #1 Ranked player.
Torchmark provides various life and health insurance products and annuities in the United States, Canada and New Zealand. It came up with a 1.34% beat in the previously reported quarter. It carries a Zacks Rank #2 (Buy).
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions. New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>